Eli Lilly stock edges up as Roche obesity-drug data keeps weight-loss race in view
Eli Lilly shares rose 0.4% to $1,067.38 Tuesday, outperforming a weaker health-care sector as investors awaited the company’s Feb. 4 results. Roche reported its experimental obesity drug CT-388 achieved up to 22.5% placebo-adjusted weight loss in a Phase II trial and plans two Phase III studies this quarter. Novo Nordisk shares slipped. Investors remain focused on demand and supply for Lilly’s weight-loss drugs.